A Closer Look at S1P Immunomodulator Therapeutics to Improve Outcomes in Patients with Relapsing Multiple Sclerosis

http://academiccme.com/wp-content/uploads/2017/03/Image-for-ACTRIMS-Brochure-wpcf_400x400.png

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: April 3, 2017 - April 2, 2018

 

Program Overview

This CME webcast was derived from content presented at a live symposium at the Advanced Curriculum for Multiple Sclerosis 2017 held in Orlando, Florida. This program will focus on the most current scientific advancements of emerging S1P immunomodulators in multiple sclerosis. Expert faculty will analyze current clinical trial data concerning S1P efficacy and safety such as head to head superiority data and add-on therapy data. Incite on how to apply the most current evidence based medicine to develop individualized treatments plans for patients with relapsing multiple sclerosis will be presented. Upon completion of this activity, physicians will gain further knowledge on how to better manage their patients with multiple sclerosis.

Target Audience

Neurologists, and other healthcare professionals who care for patients with MS.

Learning Objectives

1. Discuss the recent scientific advancements of emerging S1P immunomodulators.
2. Analyze the current clinical trial data concerning S1P efficacy and safety including, head to head superiority data and add-on therapy data.
3. Apply the most current evidence based medicine to develop individualized treatment plans for patients with relapsing multiple sclerosis.

Faculty

Lublin_HeadshotFred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

 

Freedmand headshot

Mark S. Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

Vollmer.JPG

Timothy L. Vollmer, MD
Professor Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center and Medical Director-Rocky Mountain MS Center
Aurora, Colorado

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Fred D. Lublin, MD Consultant/Advisor: AbbVie Inc.; Actelion Pharmaceuticals; Acorda Therapeutics; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mapi-Pharma Ltd.; Medday; MedImmune; POLYPHARMA; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Roche; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; ToyamaGrant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; Transparency Life SciencesSpeaker’s Bureau: Genentech, Inc.; Genzyme Corporation
Mark S. Freedman, MD  Consultant/Advisor: Actelion Pharmaceuticals; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; Genzyme Corporation; MedDay; Merck & Co.; Novartis Pharmaceuticals Corporation; Roche; sanofi-aventis U.S. LLC; Teva Canada InnovationGrant/Research Support: Genzyme CorporationSpeaker’s Bureau: Genzyme Corporation
Timothy L. Vollmer, MD Consultant/Advisor: AbbVie Inc.; Alcimed; American Academy of Neurology; CBPartners; Capmaels & Rasford LLP; Intas Pharmaceuticals Ltd.; CompassLearning, Inc.; Genentech, Inc/Roche; Genzyme Coporation; Goodwin Procter, LLP; IMS Consulting Group; MedScape; Novartis Pharmaceuticals Corporation; Oxford PharmaGenesis; Patient-Centered Outcomes Research Institute; Sanofi; Sommer Consulting; Teva Neuroscience, Inc.; The Guthy-Jackson Charitable Foundation; XenoPort, Inc.Grant/Research Support: Genzyme Corporation; Teva Pharmaceutical Industries Ltd.; NIH/NINDS; Rocky Mountain MS Center; EMD Serono, Inc.; Biogen Idec Inc.; Ono Pharmaceutical CO., LTD.; Acorda Therapeutics; MedImmune, LLC

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Actelion Pharmaceuticals, Inc

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion Pharmaceuticals, Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by AcademicCME AcademicCME Logo  

Actelion Pharmaceuticals, Inc